GT Biopharma
San Francisco, California, United States · Biotechnology · 8 employees
GT Biopharma is a biotechnology company developing novel immuno-oncology biopharmaceutical drugs using its proprietary NK cell engager (TriKE) platform technology. By leveraging this innovative approach, GT Biopharma is targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors. Traded on NASDAQ under GTBP, the company is committed to advancing cutting
Funding history
- Funding Round — $6.0M — May 2025
- Series seed — $1.3M — Mar 2025
- Funding Round — $16.0M — Jul 2021
- Funding Round — $5.6M — Jul 2020
- Funding Round — $2.4M — Jun 2020
Recent signals
- May 20, 2026: SEC 8-K (5.01): On May 20, 2026, GT Biopharma, Inc. received notification from the Nasdaq Listing Qualifications Staff that the company has been granted an additional compliance period of 180 calendar days, extending until November 16, 2026, to comply with Nasdaq Listing Rule 5550(a)(2). This rule mandates that the company's stock remains above a certain minimum bid price. The additional time allows GT Biopharma to devise strategies to improve its stock price, which could significantly impact its market presence and investor confidence. The notification indicates that the company is still in the process of meeting the necessary requirements to maintain its listing on Nasdaq, highlighting ongoing concerns regarding stock performance.
- May 27, 2025: Raised $6.0M
- Mar 07, 2025: Raised $1.3M in Series seed
- Jul 28, 2021: Raised $16.0M
- Jul 23, 2020: Raised $5.6M
- Jun 12, 2020: Raised $2.4M
- Aug 17, 2018: Raised $5.1M
- Feb 06, 2018: Raised $7.1M
See plans & pricing → Track GT Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.